Symbols

Bolt Projects Holdings Soars 109.34% on Royalty Pharma Partnership

Generated by AI AgentAinvest Pre-Market Radar

Thursday, Sep 4, 2025 5:50 am ET1min read

BSLK--

RPRX--

ZBIO--

Aime Summary

- Bolt Projects Holdings shares surged 109.34% pre-market on Sept. 4, 2025, driven by a partnership with Royalty Pharma and Zenas BioPharma.

- Royalty Pharma committed up to $300M to fund obexelimab’s U.S. launch, securing sales royalties, boosting investor confidence in Zenas’s IgG4 treatment.

- The collaboration highlights obexelimab’s medical potential and strengthens market trust in Zenas’s innovative therapies, driving growth for both firms.

Bolt Projects Holdings, Inc. shares skyrocketed by 109.34% in pre-market trading on September 4, 2025, marking a significant surge in investor interest and market sentiment.

This dramatic rise can be attributed to the recent partnership between Royalty PharmaRPRX-- and Zenas BioPharmaZBIO--, which aims to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease. Royalty Pharma's commitment to provide up to $300 million in funding, in exchange for a royalty on sales of obexelimab, has been well-received by investors, reflecting positively on Bolt ProjectsBSLK-- Holdings, Inc.

This strategic collaboration not only highlights the potential of obexelimab in the medical field but also underscores the financial backing and market confidence in Zenas BioPharma's innovative treatments. The partnership is expected to drive significant growth and development for both companies, further bolstering investor optimism in the sector.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue